Skip to main content
Top
Published in: Journal of Cancer Education 4/2017

01-12-2017

Cultural Competency Training to Increase Minority Enrollment into Radiation Therapy Clinical Trials—an NRG Oncology RTOG Study

Authors: Jessica S. Wells, Stephanie Pugh, Karan Boparai, Jessica Rearden, Katherine A. Yeager, Deborah W. Bruner

Published in: Journal of Cancer Education | Issue 4/2017

Login to get access

Abstract

Despite initiatives to increase the enrollment of racial and ethnic minorities into cancer clinical trials in the National Cancer Institute National Cancer Clinical Trials Network (NCCTN), participation by Latino and African American populations remain low. The primary aims of this pilot study are (1) to develop a Cultural Competency and Recruitment Training Program (CCRTP) for physician investigators and clinical research associates (CRAs), (2) to determine if the CCRTP increases cultural competency scores among physician investigators and CRAs, and (3) to determine the impact of the CCRTP on minority patient recruitment into NRG Oncology Radiation Therapy Oncology Group (RTOG) clinical trials. Sixty-seven CRAs and physicians participated in an in-person or online 4-h CRRTP training. Five knowledge and attitude items showed significant improvements from pre- to post-training. A comparison between enrolling sites that did and did not participate in the CCRTP demonstrated a pre to 1-year post-incremental increase in minority accrual to clinical trials of 1.2 % among participating sites. While not statistically significant, this increase translated into an additional 300 minority patients accrued to NCCTN clinical trials in the year following the training from those sites who participated in the training.
Literature
1.
go back to reference Peppercorn JM, Weeks JC, Cook EF et al (2004) Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 363:263–270CrossRefPubMed Peppercorn JM, Weeks JC, Cook EF et al (2004) Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 363:263–270CrossRefPubMed
2.
go back to reference Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA: Cancer J Clin 65(1):5–29 Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA: Cancer J Clin 65(1):5–29
3.
go back to reference Murthy VH, Krumhol HM, Gross CP (2004) Participation in cancer clinical trials. J Am Med Assoc 291:2720–2726CrossRef Murthy VH, Krumhol HM, Gross CP (2004) Participation in cancer clinical trials. J Am Med Assoc 291:2720–2726CrossRef
4.
go back to reference Wendler D, Kington R, Madans J et al (2006) Are racial and ethnic minorities less willing to participate in health research? PLoS Med 3:201CrossRef Wendler D, Kington R, Madans J et al (2006) Are racial and ethnic minorities less willing to participate in health research? PLoS Med 3:201CrossRef
5.
go back to reference Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291(22):2720–2726CrossRefPubMed Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291(22):2720–2726CrossRefPubMed
6.
go back to reference Ford JG, Howerton MW, Lai GY et al (2008) Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer 112:228–242CrossRefPubMed Ford JG, Howerton MW, Lai GY et al (2008) Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer 112:228–242CrossRefPubMed
7.
go back to reference Michaels M, Weiss ES, Guidry JA et al (2012) The promise of community-based advocacy and education efforts for increasing cancer clinical trials accrual. J Cancer Educ 27:67–74CrossRefPubMed Michaels M, Weiss ES, Guidry JA et al (2012) The promise of community-based advocacy and education efforts for increasing cancer clinical trials accrual. J Cancer Educ 27:67–74CrossRefPubMed
8.
go back to reference Leininger M (1991) The theory of culture care diversity and universality. In: Leininger M (ed) Culture care diversity and universality: a theory of nursing. National League for Nursing, New York, pp 5–65 Leininger M (1991) The theory of culture care diversity and universality. In: Leininger M (ed) Culture care diversity and universality: a theory of nursing. National League for Nursing, New York, pp 5–65
9.
go back to reference Schim SM, Doorenbos AZ, Borse NN (2005) Cultural competence among Ontario and Michigan healthcare providers. J Nurs Sch 37:354–360CrossRef Schim SM, Doorenbos AZ, Borse NN (2005) Cultural competence among Ontario and Michigan healthcare providers. J Nurs Sch 37:354–360CrossRef
10.
go back to reference Horvat L, Horey D, Romios P et al (2014) Cultural competence education for health professionals. Cochrane Database Syst Rev 10:1–84 Horvat L, Horey D, Romios P et al (2014) Cultural competence education for health professionals. Cochrane Database Syst Rev 10:1–84
11.
go back to reference Yeager KA, Bauer-Wu S (2013) Cultural humility: essential foundation for clinical researchers. Appl Nurs Res 26:251–256CrossRefPubMed Yeager KA, Bauer-Wu S (2013) Cultural humility: essential foundation for clinical researchers. Appl Nurs Res 26:251–256CrossRefPubMed
Metadata
Title
Cultural Competency Training to Increase Minority Enrollment into Radiation Therapy Clinical Trials—an NRG Oncology RTOG Study
Authors
Jessica S. Wells
Stephanie Pugh
Karan Boparai
Jessica Rearden
Katherine A. Yeager
Deborah W. Bruner
Publication date
01-12-2017
Publisher
Springer US
Published in
Journal of Cancer Education / Issue 4/2017
Print ISSN: 0885-8195
Electronic ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-016-1051-0

Other articles of this Issue 4/2017

Journal of Cancer Education 4/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine